Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC, NIPS, and Tislelizumab Conversion Therapy for Gastric Cancer
NCT07304258Phase 2Not yet recruiting
- Sponsor
- Hebei Medical University
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Hebei Medical University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07304258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07304258.